Analysis of SOX9 Expression in Colorectal Cancer

作者：Lue, Bingjian; Fang, Yihu; Xu, Jing; Wang, Lipei; Xu, Fangying; Xu, Enping; Huang, Qiong; Lai, Maode^*

来源：American Journal of Clinical Pathology, 2008, 130(6): 897-904.

DOI：10.1309/AJCPW1W8GJBQGCNI

• Colorectal cancer
• SOX9
• beta-Catenin
• Prognosis

Our purpose was to investigate the role of SOX9, a novel downstream molecule of beta-catenin, in colorectal cancer. Expression of SOX9 and beta-catenin was detected by immunostaining, quantitative real-time reverse transcription-polymerase chain reaction (Q-PCR), and Western blot in colorectal cancer. The correlation between SOX9 or P-catenin expression and clinicopathologic parameters was also analyzed. Immunostaining, Q-PCR, and Western blot consistently confirmed SOX9 up-regulation in colorectal cancer compared with normal mucosa (P < .05). Immunostaining showed more SOX9+ cells in the lower zone of colonic crypts than in the upper zone (P < .05). Cancers with strong SOX9 immunostaining were significantly associated with a lower 5-year overall survival (40% [17/43] vs low expression, 69% [66/95]; P < .01). The Cox proportional hazards model showed that strong SOX9 expression was an independent adverse prognosticator in colorectal cancer (P < .05). The detection of SOX9 expression might contribute to predicting clinical outcomes for patients with colorectal cancer.

• 出版日期2008-12
• 单位浙江大学